Pharmacology of hyperkalemia
Acute and chronic hyperkalemia (HK) is a frequent occurrence in patients with heart failure resulting from decreased renal function, dysfunctional homoeostatic mechanisms and the effect of cardiovascular drugs. Drugs such as renin-angiotensin-aldosterone system inhibitors (RAASi), angiotensin receptor-neprilysin inhibitor and beta-blockers can cause drug-induced HK by interfering with potassium excretion. Up until now therapies for acute and chronic HK have been limited to drugs that can be used in the acute and sub-acute phase. However, new therapeutic options for the acute and chronic therapy of HK have become available in recent years. Patiromer and sodium zirconium cyclosilicate are effective for both the acute and long-term treatment of HK in patients with cardio-renal syndrome and in those with heart failure. These medicines significantly reduce serum potassium in patients with HK on RAASi and enable the use and up-titration of RAASi in patients who are not optimally treated.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Giornale italiano di cardiologia (2006) - 22(2021), 12 Suppl 1 vom: 01. Dez., Seite e8-e12 |
| Sprache: |
Italienisch |
|---|
| Weiterer Titel: |
Strategie farmacologiche per il trattamento dell’iperpotassiemia |
|---|
| Beteiligte Personen: |
Rosano, Giuseppe M C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiotensin-Converting Enzyme Inhibitors |
|---|
| Anmerkungen: |
Date Completed 24.12.2021 Date Revised 01.04.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1714/3716.37068 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334717523 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334717523 | ||
| 003 | DE-627 | ||
| 005 | 20231225224314.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||ita c | ||
| 024 | 7 | |a 10.1714/3716.37068 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1115.xml |
| 035 | |a (DE-627)NLM334717523 | ||
| 035 | |a (NLM)34935774 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a Rosano, Giuseppe M C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacology of hyperkalemia |
| 246 | 3 | 3 | |a Strategie farmacologiche per il trattamento dell’iperpotassiemia |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.12.2021 | ||
| 500 | |a Date Revised 01.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Acute and chronic hyperkalemia (HK) is a frequent occurrence in patients with heart failure resulting from decreased renal function, dysfunctional homoeostatic mechanisms and the effect of cardiovascular drugs. Drugs such as renin-angiotensin-aldosterone system inhibitors (RAASi), angiotensin receptor-neprilysin inhibitor and beta-blockers can cause drug-induced HK by interfering with potassium excretion. Up until now therapies for acute and chronic HK have been limited to drugs that can be used in the acute and sub-acute phase. However, new therapeutic options for the acute and chronic therapy of HK have become available in recent years. Patiromer and sodium zirconium cyclosilicate are effective for both the acute and long-term treatment of HK in patients with cardio-renal syndrome and in those with heart failure. These medicines significantly reduce serum potassium in patients with HK on RAASi and enable the use and up-titration of RAASi in patients who are not optimally treated | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Potassium |2 NLM | |
| 650 | 7 | |a RWP5GA015D |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Giornale italiano di cardiologia (2006) |d 2006 |g 22(2021), 12 Suppl 1 vom: 01. Dez., Seite e8-e12 |w (DE-627)NLM16119561X |x 1972-6481 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:12 Suppl 1 |g day:01 |g month:12 |g pages:e8-e12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1714/3716.37068 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2021 |e 12 Suppl 1 |b 01 |c 12 |h e8-e12 | ||